In mammals, one of the most pronounced consequences of viral infection is the induction of type I interferons, cytokines with potent antiviral activity. Schlafen (Slfn) genes are a subset of interferon-stimulated early response genes (ISGs) that are also induced directly by pathogens via the interferon regulatory factor 3 (IRF3) pathway 1 . However, many ISGs are of unknown or incompletely understood function. Here we show that human SLFN11 potently and specifically abrogates the production of retroviruses such as human immunodeficiency virus 1 (HIV-1). Our study revealed that SLFN11 has no effect on the early steps of the retroviral infection cycle, including reverse transcription, integration and transcription. Rather, SLFN11 acts at the late stage of virus production by selectively inhibiting the expression of viral proteins in a codon-usage-dependent manner. We further find that SLFN11 binds transfer RNA, and counteracts changes in the tRNA pool elicited by the presence of HIV. Our studies identified a novel antiviral mechanism within the innate immune response, in which SLFN11 selectively inhibits viral protein synthesis in HIV-infected cells by means of codon-bias discrimination.
In mammals, one of the most pronounced consequences of viral infection is the induction of type I interferons, cytokines with potent antiviral activity. Schlafen (Slfn) genes are a subset of interferon-stimulated early response genes (ISGs) that are also induced directly by pathogens via the interferon regulatory factor 3 (IRF3) pathway 1 . However, many ISGs are of unknown or incompletely understood function. Here we show that human SLFN11 potently and specifically abrogates the production of retroviruses such as human immunodeficiency virus 1 (HIV-1). Our study revealed that SLFN11 has no effect on the early steps of the retroviral infection cycle, including reverse transcription, integration and transcription. Rather, SLFN11 acts at the late stage of virus production by selectively inhibiting the expression of viral proteins in a codon-usage-dependent manner. We further find that SLFN11 binds transfer RNA, and counteracts changes in the tRNA pool elicited by the presence of HIV. Our studies identified a novel antiviral mechanism within the innate immune response, in which SLFN11 selectively inhibits viral protein synthesis in HIV-infected cells by means of codon-bias discrimination.
SLFN genes encode a family of proteins limited to mammalian organisms. Nine murine and six human SLFN genes share a conserved NH2-terminus containing a putative AAA-domain, and long SLFN genes possess motifs resembling DNA/RNA helicase domains, a trait they share with the nucleic acid sensors RIG-I and MDA-5 2 . Beyond that, SLFN proteins harbour no sequence similarity to other proteins. In vivo, short and long murine SLFN proteins inhibit T-cell development [3] [4] [5] , and levels of murine SLFN proteins are elevated after infection with Brucella or Listeria Fig. 1b) . Notably, we observed a striking difference in SLFN levels between HEK293 (293) and HEK293T (293T) cells ( Supplementary Fig. 1b) , and exploited this differential expression to focus on SLFN11 for further studies. We further used SLFN11-targeted short hairpin RNA to generate stable 293 cells that specifically lack SLFN11 expression (293shRNA SLFN ) ( Supplementary Fig. 1c, d ).
To test whether lack of SLFN11 in 293shRNA SLFN HEK293T cells are used as packaging cells for production of retroviruses, and we therefore considered the possibility that virus production rather than the response towards them is afflicted by SLFN11. Indeed, 293T cells produced markedly higher HIV VSV-G (Fig. 1b) or MCSV ( Supplementary Fig. 3a ) titres than 293 cells from the viral vectors pNL4-3.Luc.R 1 E 2 or MSCV-IRES-GFP, respectively. Most importantly, this increase in viral titre was also clearly evident in 293shRNA SLFN cells, whereas 293 and 293shRNA Ctl cells produced the same low levels of virus ( Fig. 1b and Supplementary Fig. 3a) . Notably, the modulation of virus production is limited to particular viruses, as fabrication of retroviruses ( Fig. 1b and Supplementary Fig. 3a ), but not of AAV ( Supplementary Fig. 3c ), was affected by SLFN11. We also did not observe any modulation of ISGs such as ISG15, ISG54 or APOBEC3G (not shown) as a consequence of SLFN11 expression, supporting the notion that SLFN11 does not create a general virusresistant phenotype.
To corroborate that the observed differences are attributable to dissimilar SLFN11 expression, we expressed full-length SLFN11 (amino acids 1-901) in 293T cells and analysed their ability to produce HIV VSV-G . Indeed, SLFN11 strongly inhibited HIV VSV-G (Fig. 1a) or MSCV ( Supplementary Fig. 3b ) production from 293T cells, with the inhibitory activity residing in the AAA-domain-containing, amino-terminal region (SLFN11-N; amino acids 1-579). No effect of the isolated carboxy-terminal region (SLFN11-C; amino acids 523-901) harbouring the putative helicase sequence was observed ( Fig. 1a and Supplementary Fig. 3b ). Intriguingly, SLFN5 failed to inhibit retrovirus production but yielded slightly elevated viral titres, illustrating specificity among SLFN proteins in their antiviral activity.
To discern whether SLFN11 reduced the number or the viability of released virus, we measured p24 capsid and viral RNA (vRNA) levels in supernatants of pNL4-3.Luc.R (Fig. 1c and d) or vRNA ( Fig. 1e and f) concentration patterns closely matched the titre results from infection assays, demonstrating that SLFN11 diminishes the number of viral particles released from the cells.
To assess a possible reduction of intracellular vRNA, we determined its levels in 293T cells expressing chloramphenicol acetyl transferase (CAT), SLFN5, SLFN11, SLFN11-N or SLFN11-C (Fig. 1g) , as well as in 293, 293shRNA
Ctl and 293shRNA SLFN cells (Fig. 1h) . In contrast to the pronounced variations in extracellular vRNA, only insignificant differences in intracellular vRNA were evident among those cells. We also analysed vRNA in the cytoplasmic fraction specifically, as nuclear export of unspliced vRNA is a hallmark of retroviral RNA processing [6] [7] [8] , but again found no significant alterations attributable to SLFN11 (Supplementary Fig. 4a ).
Unlike in BST2-expressing cells 9, 10 , electron-microscopic analysis failed to document accumulation of virions inside or on the surface of virus-producing cells in the presence of SLFN11 ( Supplementary  Fig. 4b ). As such, SLFN11 greatly diminishes the formation of viral particles inside the cell, despite the fact that vRNA is equally available.
When the two cell sets were analysed for the expression of viral proteins encoded by pNL4-3.Luc.R 1 E 2 , we noted a marked effect of SLFN11 on p55 Gag and p24 capsid proteins 11 ( Fig. 2a, b ). To create a clearer picture of the effect of SLFN11 on p55, we abolished expression of the viral protease by introducing a stop codon into pro in pNL4-3.Luc.R 1 E 2 . As anticipated, p24 could no longer be detected; however, modulation of p55 expression by SLFN11 was clearly present (Supplementary Fig. 5a ). As with gag-derived proteins, SLFN11 had a notable effect on the protein levels of RT, Vif, Vpu and Vpr (Fig. 2a,  b) . Intriguingly, we did not observe any reduction of enhanced green fluorescent protein (EGFP) derived from a co-transfected vector, or of GAPDH (Fig. 2a, b, bottom) , indicating that the limited viral protein production is not due to a global shutdown of protein synthesis.
Even more surprising was that luciferase expression, coded in pNL4-3.Luc.R 1 E 2 in place of nef, was mostly impervious to SLFN11 (Fig. 2c, top) , contrasting the SLFN11-mediated diminishment of other proteins encoded on this vector. Notably, Nef expression was inhibited by SLFN11 in the context of pNL4-3-DEnv-EGFP, which has part of env replaced by EGFP, but retains nef in its original position. (Fig. 2c, bottom) . We thus conclude that SLFN11 selectively suppresses viral protein expression via transcript-intrinsic properties rather than external factors or positional elements. This notion is further corroborated by the fact that SLFN11 had no effect on Rev response element (RRE)-mediated events such as nuclear export of unspliced vRNA ( Supplementary Fig. 5b ).
Viral genomes have biased nucleotide compositions different from human genes [12] [13] [14] [15] [16] [17] [18] . Extremely high frequencies of A nucleotides are found in the RNA genomes of lentiviruses and influenza virus 13, 17, 19, 20 . Wild isolates of HIV-1, particularly gag and pol sequences, are characterized by low GC content and suboptimal codon usage compared to the host cell preference 14, [21] [22] [23] [24] . The unusual rare codon bias favours A/U in the third position, which induces ribosome pausing and inefficient translation. As the inhibitory effect of SLFN11 on viral protein expression is intrinsic to the transcripts, we proposed that SLFN11 exploits viral codon preferences to specifically attenuate viral protein synthesis. We therefore generated vectors containing only the open reading frame of HIV-1 gag with either viral codon-bias (Gag vir ), or synonymous substitutions optimizing for human cell expression (Gag opt ). As shown in Fig. 2d , SLFN11 strongly affected expression of Gag vir , but was without consequence for Gag opt expression. Differences in translation initiation are not likely, as both Gag vir and Gag opt contain the same translation start sequences. This finding strongly indicates that SLFN11 is exploiting the distinct viral codon bias to selectively attenuate the expression of viral proteins.
Previous reports indicated changes in cellular tRNA levels after HIV infection 20 , prompting us to investigate whether SLFN11 alters the tRNA composition in the absence or presence of HIV. Using tRNA arrays 25, 26 , we observed little to no changes in tRNA levels as a 
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consequence of SLFN11 expression (Fig. 3a, left column) . However, whereas HIV triggered substantial changes in tRNA concentrations in SLFN11-knockdown cells, no changes were observed in the presence of SLFN11 (Fig. 3a, middle and right) . Thus, SLFN11 counteracts HIVinduced changes in tRNA composition, presumably initiated to promote viral protein synthesis. To test whether SLFN11 interacts directly with tRNA, we used human tRNA as electrophoretic mobility shift assay (EMSA) probe with fast protein liquid chromatography (FPLC)-purified His-conjugated SLFN11-N. As shown in Fig. 3b, SLFN11-N produced a clear shift of the tRNA in a dose-dependent manner. The shifted band was competed with unlabelled tRNA, but not in-vitrotranscribed vRNA (Fig. 3b) , and was disrupted by an antibody against SLFN11 (Fig. 3c) . To determine whether SLFN11 has binding preference for particular tRNAs, we performed EMSAs with increasing amounts of SLFN11-N to obtain approximately 50% shifting efficiency ( Supplementary Fig. 6 ). When the shifted (S), unshifted (U) and total tRNA (T) bands were isolated and recovered tRNAs hybridized to tRNA arrays, no enrichment of particular tRNAs in the shifted band was noticeable (Supplementary Fig. 6 ), indicating a lack of discerning binding preference of SLFN11-N.
The results shown lead to the premise that any protein that uses similar codon usage as HIV would be modulated by HIV and/or SLFN11. To demonstrate unequivocally that codon-bias rather than cryptic regulatory elements in gag accounted for the influence of SLFN11, we tested this hypothesis using non-viral proteins. Natural green fluorescent protein (GFP) harbours a similar codon-bias as that of HIV, whereas EGFP has been optimized for mammalian expression by substituting synonymous codons of highly expressed human genes throughout the GFP open reading frame 22 . As anticipated, co-transfection of pNL4-3.Luc.R 1 E 2 with V5-tagged GFP and Myc-tagged EGFP in the absence of SLFN11 resulted in increased GFP, but not EGFP, expression (not shown). Most importantly, SLFN11 inhibited the expression of GFP in a manner identical to viral proteins, whereas EGFP was largely refractory to suppression by SLFN11 (Fig. 3d, e) . As (E)GFP protein levels have been normalized to their respective messenger RNA levels (Fig. 3e) , we conclude that any differences in GFP expression are the consequence of altered protein synthesis rather than variations in transcription or mRNA stability.
Finally, to demonstrate that the anti-retroviral effects of SLFN11 are not limited to a system using HIV VSV-G and 293 cells, we used CEM cells, a T-cell line widely used to assess HIV replication kinetics. Human peripheral blood mono-nuclear cells (PBMCs) display similar levels of SLFN11 after IFN-b stimulation as CEM cells (Fig. 4a) . Control or SLFN11-directed shRNAs were used to generate stable CEM variants (Fig. 4b) , and the resulting CEMshRNA Ctl and CEMshRNA SLFN cells and parental CEM cells were infected with wild-type X4-HIV-1 LAI , and viral replication was assessed via p24 enzyme-linked immunosorbent assays (ELISA) of the supernatants. Relative abundances of mature tRNA species were analysed by microarray as described 25, 26 . b, Left: increasing amounts of SLFN11-N or GFP were incubated with 32 P-labelled tRNA and subjected to EMSA. Right: 2 3 or 10 3 unlabelled tRNA or in-vitro-transcribed vRNA corresponding to the gag-pol frameshifting sequence (120 bases) were added to the binding reaction. c, As in b, except non-specific (NS) or anti-SLFN11 (Anti-S11) monoclonal antibody was added to the binding reaction. d, 293T cells were transfected with V5-tagged GFP, Myc-tagged EGFP and pNL4-3.Luc.R 
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As anticipated, CEM and CEMshRNA Ctl cells produced comparable viral titres at all time points. In contrast, CEMshRNA SLFN cells facilitated significantly enhanced HIV-1 replication, yielding an exponentially increasing difference in viral titres (Fig. 4c) . A second CEMshRNA SLFN cell line established by means of a distinct SLFN11 shRNA further corroborated these results (Supplementary Fig. 7) .
In summary, systematic analysis of the HIV replication cycle revealed that SLFN11 does not inhibit reverse transcription, integration or production and nuclear export of viral RNA, nor did we observe a block in budding or release of viral particles. However, we discovered a selective inhibition in the synthesis of virally encoded proteins. Intriguingly, a specific inhibition of viral protein synthesis in HIVinfected cells in response to interferon was previously observed, but the factors responsible for the effect were not identified 27 . We postulate that SLFN11 acts at the point of virus protein synthesis by exploiting the unique viral codon bias towards A/T nucleotides. This model supports the notion that the antiviral activity of SLFN11 extends to other viruses with rare codon bias such as influenza, but apparently not to AAV or HSV. The exact mechanism by which HIV alters tRNA function in its favour and how SLFN11 counteracts this process will require considerable further analysis. Evidently, SLFN11 interacts with all tRNAs in vitro. Direct binding of SLFN11 to tRNA offers the possibility that SLFN11 either sequesters tRNAs, prevents their maturation via post-transcriptional processing or accelerates their deacylation. In either case, if already rare tRNAs are further reduced, tRNA availability might manifest as the rate-limiting step in the synthesis of proteins involving those tRNAs. In contrast, a lesser or no impact would be expected on proteins synthesized via plentiful tRNAs, as even if a fraction of those tRNAs is 'eliminated', translation initiation will likely remain the rate-limiting event. In conclusion, our results establish SLFN11 as a potent, interferon-inducible restriction factor against retroviruses such as HIV, mediating its antiviral effects on the basis of codon usage discrimination.
METHODS SUMMARY
Plasmids and antibodies. SLFN5 and SLFN11 were cloned into pcDNA6/V5-His. PCR fragments of SLFN11 were cloned into pcDNA6/V5-His to generate SLFN11-N (amino acids 1-579) and SLFN11-C (amino acids 523-901). The pNL4-3.Luc.R 1 E 2 HIV-1 vector has been described previously 28 . SLFN11 antibodies were from Sigma and Abmart. pNL4-3-DEnv-EGFP, pNL-GFP-RRE(SA) and antibodies against HIV-1 proteins were obtained through the NIH AIDS Research and Reference Reagent Program. Generation of Gag vir , Gag opt and (E)GFP vectors is in Methods. pLKO.1 shRNA lentivirus constructs were from Open Biosystems. Virus production and titre assays. HIV production was determined by transfection of pNL4-3.Luc.R 1 E 2 and pCMV-VSV-G into cells of interest. Supernatants were used to spin-infect HEK293T cells, and luciferase was measured by BrightGlo Luciferase Assay (Promega). p24 ELISAs were performed at the Center for AIDS Research, UCSD using Alliance p24 ELISA kits (Perkin Elmer). HIV replication kinetics. Wild type X4 strain of HIV-1 LAI was used to inoculate CEM, CEMshRNA
Ctl and CEMshRNA SLFN cells at a multiplicity of infection of 0.01, and viral titres were measured by p24 ELISA. Data analysis and presentation. Unless indicated otherwise, results presented in graphs are average 6 s.d. of at least three independent transfections or infections. For immunoblots, a representative of at least three independent transfections or infections is shown.
Full Methods and any associated references are available in the online version of the paper.
METHODS
Cell culture. HEK293, HEK293T, NIH3T3, HeLa, HFFs (human foreskin fibroblasts) and their derivative cells were maintained in high glucose DMEM. CEM and their derivative cells were maintained in RPMI 1640 medium. Both media were supplemented with 10% heat-inactivated fetal bovine serum, 100 U ml 21 penicillin, 100 mg ml 21 streptomycin, 2 mM L-glutamine, MEM non-essential amino acids, 1 mM sodium pyruvate and 55 mM 2-mercaptoethanol. The Phoenix amphotropic retrovirus packaging cell line (293T) originates from the laboratory of G. Nolan. Human PBMCs were obtained from the San Diego Blood Bank. Plasmids. The template vectors encoding SLFN5 and SLFN11 sequences were acquired from Open Biosystems (Human MGC Verified FL cDNA (IRAU), clone ID 40123369 and 6258140). The coding sequences were amplified by PCR with PfuUltra (Stratagene) and subcloned into the pcDNA6/V5-His vector (Invitrogen) for mammalian cell expression. Partials of the human SLFN11 coding sequence (GenBank accession no. NM_001104587) were amplified by PCR and subcloned into the pcDNA6/V5-His vector to generate the SLFN11-N (amino acids 1-579) and SLFN11-C (amino acids 523-901) truncation mutants. The pcDNA6/V5-His CAT (chloramphenicol acetyl transferase) vector was generated the same way using pcDNA5/FRT/TO CAT (Invitrogen) as the PCR template for the CAT sequence opt was generated through PCR amplification of the gag sequence from p96ZM651gag-opt (NIH AIDS Research & Reference Reagent Program, no. 8675) in which the entire gag sequence was converted to use codon usage in line with highly expressed human genes. GFP and EGFP sequences were cloned into pcDNA6.2/V5 using the pcDNA6.2/GW/D-TOPO kit (Invitrogen). The GFP sequence was tagged with a V5 epitope whereas the EGFP sequence was tagged with a Myc tag (59-GAGCAGAAGCTGATCA GCGAGGAGGACCTG-39). The GFP sequence used retains most of the original wild-type protein sequence. The EGFP sequence contains more than 190 silent base changes following human genes codon-usage preferences. Sequences flanking both GFP and EGFP translation initiation site have been converted to a Kozak consensus translation initiation site (59-CACCATGGTGAGC…) to ensure identical translation initiation efficiency in eukaryotic cells. shRNA constructs. The pLKO.1 shRNA lentivirus constructs (TRCN0000148990, TRCN0000152230, TRCN0000155578, TRCN0000157747, TRCN0000152057, TRCN0000155564) against SLFN11 were obtained from The RNAi Consortium via Open Biosystems. Construct TRCN0000148990 (59-CCGGGCTCAGAA TTTCCGTACTGAACTCGAGTTCAGTACGGAAATTCTGAGCTTTTTTG-39) produced maximum SLFN11 knockdown at the protein level and was thus designated as SLFN11 shRNA in this study. pLKO.1-Blasticidin construct was created by replacing puromycin resistance gene of the original pLKO.1 construct with blasticidin resistance gene using BamHI and KpnI sites. The control shRNA construct in the same pLKO.1 vector system (59-CCGGTGAAGAACTAA CCCGGGACTTCTCGAGAAGTCCCGGGTTAGTTCTTCATTTTTG-39) was also obtained from The RNAi Consortium via Open Biosystems and does not match any human genes. Antibodies. Anti-SLFN11 antibody for immunoblotting was purchased from Sigma Life Sciences (Atlas Antibodies). Monoclonal anti-SLFN11 antibody for supershift experiments was custom-generated by Abmart. Murine anti-V5 antibody (E10) antibodies were from eBiosciences and Santa Cruz Biotechnology, respectively. Goat polyclonal anti-luciferase antibody was obtained from Promega, rabbit anti-GFP (D5.1) and rabbit anti-GAPDH monoclonal antibodies (14C10) were RNasin Plus RNase Inhibitor (Promega) and 1 mM DTT). Intact cell nuclei were removed by centrifugation at 4 uC for 2 min at 300g, and cytoplasmic RNA was extracted from the remaining supernatant. RNA was cleaned using Ambion DNAfree kits and reverse transcribed with Applied Biosystems' High Capacity cDNA Reverse Transcription kit. qPCR was performed on Applied Biosystems 7000 Sequence Detection System or Applied Biosystems StepOnePlus Real-Time PCR System using Power SYBR Green PCR Master Mix. Relative RNA level were calculated after normalization to 18S rRNA unless specified otherwise. The following primer sequences were used in these assays: SLFN5 forward 59-CAAGCCTGTGTGCATTCATAA-39, reverse 59-TCTGGAGTATATACCA CTCTGTCTGAA-39; SLFN11 forward 59-AAGGCCTGGAACATAAAAAGG-39, reverse 59-GGAGTATATCGCAAATATCCTGGT-39; SLFN12 forward 59-CTT TGTTCAACACGCCAAGA-39, reverse 59-ATGCAGTGTCCAAGCAGAAA-39; SLFN13 forward 59-GAGAAAATGATGGACGCAGAT-39, reverse 59-AGACTC AAAGGCCTCAGCAA-39; SLFN12L forward 59-GAAAGTCAGTTTCTGAGG AATTTCA-39, reverse 59-CCAGCTCAGCATAGTTTGTGTC-39; SLFN14 forward 59-GGTGGTCATGATGCTGGATA-39, reverse 59-TGATGAAATCA GGCAAGAGTTG-39; ISG54 forward 59-TGGTGGCAGAAGAGGAAGAT-39, reverse 59-CCAAGGAATTCTTATTGTTCTCACT-39; TBP forward 59-GCTGG CCCATAGTGATCTTT-39, reverse 59-CTTCACACGCCAAGAAACAGT-39; 18S rRNA forward 59-GGATGCGTGCATTTATCAGA-39, reverse 59-GTTGATA GGGCAGACGTTCG-39; GFP forward 59-CTGGAGTTGTCCCAATTCTTG-39, reverse 59-TCACCCTCTCCACTGACAGA-39; EGFP forward 59-CAGCAGAA CACCCCCATC-39, reverse 59-TGGGTGCTCAGGTAGTGGTT-39; luciferase forward 59-AGGTCTTCCCGACGATGA-39, reverse 59-GTCTTTCCGTGCTCC AAAAC-39; HIV p24 forward 59-TGCATGGGTAAAAGTAGTAGAAGAGA-39, reverse 59-TGATAATGCTGAAAACATGGGTA-39. Generation of stable SLFN11 knockdown HEK293 and CEM cell lines. HEK293T cells were transfected with the SLFN11 shRNA or control lentivirus vector and the lentivirus packaging vectors psPAX2 and pMD2.G using Lipofectamine 2000 (Invitrogen) according to the manufacturer's protocol. The cell culture medium was collected and replaced with fresh medium 48, 72 and 96 h after the transfection. The combined supernatants were cleared by centrifugation at 1,000g at 4 uC for 15 min. To generate stable SLFN11 knockdown HEK293 cell lines, cleared supernatants were added to pre-plated HEK293 cells in the presence of 8 mg ml 21 polybrene and centrifuged at 600g for 90 min at room temperature. After 48 h, infected cells were subject to resistance selection with 2 mg ml 21 puromycin. The efficiency of SLFN11 knockdown in the selected cells was assayed by qPCR and immunoblotting. To generate stable SLFN11 knockdown CEM cell lines, cells were first infected and selected as outlined above. Although the same shRNA construct was used, knockdown in CEM cells was less efficient when compared to HEK293 cells. To improve the SLFN11 knockdown in CEM cells, puromycin-selected CEM cells were re-infected with the pLKO.1-Blasticidin construct carrying the same shRNA and subject to resistance selection with 15 mg ml 21 blasticidin and 2 mg ml 21 puromycin. Such double-selected cells displayed a . 90% knockdown of SLFN11 (see Fig. 4b ). Assay for MSCV, HIV and AAV production. To analyse MSCV retrovirus production, MSCV-IRES-GFP (MIG) plasmid and pCL Eco packaging vector were transfected into the cells of interest using Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions. After 24 h the cells were moved to 32 uC, and supernatants were collected after 24 h and cleared by centrifugation. Transfection efficiency was determined by analysis of GFP expression in the cells and was subsequently incorporated into the virus titre calculations. The amount of (infectious) virus particles in the supernatants was determined by both infection assays and qPCR analysis of viral RNA. For infection assays, pre-plated NIH3T3 cells were spin-infected with tenfold serially diluted supernatants in the presence of 8 mg ml 21 polybrene at 600g for 90 min at room temperature. 48 h after the spin infection, the NIH3T3 cells were examined for GFP expression by flow cytometry, and the number of GFP 1 cells was used to calculate relative viral titres. For viral RNA qPCR assays, viral RNA was extracted from the virus supernatant and LETTER RESEARCH
